Dynavax's herpes zoster vaccine phase I/II trial results are comparable to GlaxoSmithKline's Shingrix vaccine.

According to the Zhidao Financial APP, Dynavax Technologies (DVAX.US) has risen by about 7%. Previously, the company announced that the immune response triggered by its investigational shingles vaccine Z-1018 in Phase I/II trials is comparable to GlaxoSmithKline's (GSK.US) Shingrix vaccine.